2-230910644-C-T
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PP3_Moderate
The NM_005683.4(GPR55):c.319G>A(p.Gly107Arg) variant causes a missense change. The variant allele was found at a frequency of 0.0000335 in 1,613,756 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.000039 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000033 ( 0 hom. )
Consequence
GPR55
NM_005683.4 missense
NM_005683.4 missense
Scores
9
7
3
Clinical Significance
Conservation
PhyloP100: 5.01
Genes affected
GPR55 (HGNC:4511): (G protein-coupled receptor 55) This gene belongs to the G-protein-coupled receptor superfamily. The encoded integral membrane protein is a likely cannabinoid receptor. It may be involved in several physiological and pathological processes by activating a variety of signal transduction pathways. [provided by RefSeq, Aug 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 4 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.928
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GPR55 | NM_005683.4 | c.319G>A | p.Gly107Arg | missense_variant | 2/2 | ENST00000650999.1 | NP_005674.2 | |
GPR55 | XM_005246952.5 | c.319G>A | p.Gly107Arg | missense_variant | 2/2 | XP_005247009.1 | ||
GPR55 | XM_011512175.4 | c.319G>A | p.Gly107Arg | missense_variant | 2/2 | XP_011510477.1 | ||
GPR55 | XM_011512176.3 | c.319G>A | p.Gly107Arg | missense_variant | 2/2 | XP_011510478.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GPR55 | ENST00000650999.1 | c.319G>A | p.Gly107Arg | missense_variant | 2/2 | NM_005683.4 | ENSP00000498258.1 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152100Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
6
AN:
152100
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000160 AC: 4AN: 250500Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135572
GnomAD3 exomes
AF:
AC:
4
AN:
250500
Hom.:
AF XY:
AC XY:
3
AN XY:
135572
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000328 AC: 48AN: 1461538Hom.: 0 Cov.: 32 AF XY: 0.0000316 AC XY: 23AN XY: 727096
GnomAD4 exome
AF:
AC:
48
AN:
1461538
Hom.:
Cov.:
32
AF XY:
AC XY:
23
AN XY:
727096
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152218Hom.: 0 Cov.: 32 AF XY: 0.0000537 AC XY: 4AN XY: 74424
GnomAD4 genome
AF:
AC:
6
AN:
152218
Hom.:
Cov.:
32
AF XY:
AC XY:
4
AN XY:
74424
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
3
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 27, 2024 | The c.319G>A (p.G107R) alteration is located in exon 2 (coding exon 1) of the GPR55 gene. This alteration results from a G to A substitution at nucleotide position 319, causing the glycine (G) at amino acid position 107 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Uncertain
T;T;T;.
Eigen
Pathogenic
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Benign
.;T;.;T
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D;D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Pathogenic
M;M;M;.
PrimateAI
Uncertain
T
PROVEAN
Uncertain
.;D;D;D
REVEL
Pathogenic
Sift
Uncertain
.;D;D;D
Sift4G
Benign
T;T;T;D
Polyphen
D;D;D;.
Vest4
MutPred
Loss of catalytic residue at F110 (P = 0.2357);Loss of catalytic residue at F110 (P = 0.2357);Loss of catalytic residue at F110 (P = 0.2357);Loss of catalytic residue at F110 (P = 0.2357);
MVP
MPC
1.0
ClinPred
D
GERP RS
Varity_R
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at